Sanofi announces new Country Lead for the UK & Ireland

Reading, Wednesday 7^th February 2024. Sanofi today announced that Rippon Ubhi has been appointed as Country Lead for the UK and Ireland, taking over from Jessamy Baird effective immediately. Rippon is currently General Manager for Specialty Care in the UK & Ireland, a role she will continue alongside her new appointment.

 Rippon brings close to 20 years of senior commercial leadership experience in global, international (emerging markets including China) and affiliate organisations including having lived and worked in Japan, United States and the UK over the past decade, working across pre-launch, launch and established business & culture environments. She joined Sanofi in late 2022 after 18 years at AstraZeneca and has since played a pivotal role in leading the UK & Ireland business to success, in particular across the Immunology, Rare Diseases, Neurology and Oncology franchises.

Shannon Resetich

Head of key markets, Sanofi Specialty Care

“Rippon’s wealth of experience and proven history of success make her the perfect candidate for this critical role. She is a skilled business leader, able to inspire her teams and collaborate with partners across the healthcare sector. I’m excited to see how her energy, passion and strategic leadership will drive us forwards on our next chapter of success in the UK and Ireland.”

 In her new role, Rippon will work with the UK and Ireland Governments, the National Health Service (NHS) in the UK, Health Service Executive (HSE) in Ireland, as well as other partners to improve access to innovative medicines and vaccines for patients and the public. In the UK, she will be looking to champion the Life Sciences sector and help return it to international competitiveness as an attractive location for inward investment.

Rippon Ubhi

Country Lead and General Manager for Specialty Care, Sanofi UK & Ireland

“I’m honoured to be appointed this role at such an exciting time at Sanofi. We’re progressing rapidly to deliver our ambition to be the leading immunology company by 2030 and to be the first pharmaceutical company powered by artificial intelligence at scale. We have a talented and diverse group of individuals in our UK and Ireland organisation and I’m confident we will deliver for our business, the health system and for patients.”